{"title":"Bexagliflozin (Brenzavvy)——治疗2型糖尿病的第五种SGLT2抑制剂。","authors":"","doi":"10.58347/tml.2023.1683b","DOIUrl":null,"url":null,"abstract":"Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the FDA to improve glycemic control in adults with type 2 diabetes. It is the fifth SGLT2 inhibitor to be approved in the US for this indication.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bexagliflozin (Brenzavvy) - A fifth SGLT2 inhibitor for type 2 diabetes.\",\"authors\":\"\",\"doi\":\"10.58347/tml.2023.1683b\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the FDA to improve glycemic control in adults with type 2 diabetes. It is the fifth SGLT2 inhibitor to be approved in the US for this indication.\",\"PeriodicalId\":54742,\"journal\":{\"name\":\"Medical Letter on Drugs and Therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2023-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Letter on Drugs and Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.58347/tml.2023.1683b\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Letter on Drugs and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.58347/tml.2023.1683b","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Bexagliflozin (Brenzavvy) - A fifth SGLT2 inhibitor for type 2 diabetes.
Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the FDA to improve glycemic control in adults with type 2 diabetes. It is the fifth SGLT2 inhibitor to be approved in the US for this indication.
期刊介绍:
The Medical Letter, Inc. is committed to providing objective, practical, and timely information on drugs and treatments of common diseases to help our readers make the best decisions for their patients—without the influence of the pharmaceutical industry.
The Medical Letter On Drugs and Therapeutics is a biweekly publication that provides:
Evidence-based, peer-reviewed evaluations of new FDA-approved drugs with conclusions reached by a consensus of experts
New information on previously approved drugs including pivotal clinical trials, new indications, and safety warnings
Consensus recommendations for the preferred and alternative treatments for common disorders
Comparative reviews of drugs for a given indication with particular attention to clinical efficacy, adverse effects, drug interactions, and cost.